DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France

Active, not recruiting

Conditions: Urothelial Carcinoma

Interventions: Drug: nivolumab

First Posted Date: 2024-05-20

Last Posted Date: 2025-04-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 300

Registration Number: NCT06421311

Locations: 🇫🇷
Local Institution - 0001, Paris, France
🇫🇷
ICANS Institut de Cancérologie Strasbourg Europe, Strasbourg, France

Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Drug: BMS-986497

First Posted Date: 2024-05-17

Last Posted Date: 2025-04-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 35

Registration Number: NCT06419634

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸
Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
Local Institution - 0010, Chicago, Illinois, United States

and more 8 locations

A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis

Phase 4

Active, not recruiting

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: BMS-986374

First Posted Date: 2024-05-02

Last Posted Date: 2025-04-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 84

Registration Number: NCT06396039

Locations: 🇨🇳
Local Institution - 0008, Shenzhen, Guangdong, China
🇨🇳
Local Institution - 0002, Beijing, Beijing, China
🇨🇳
Local Institution - 0012, Guangzhou, Guangdong, China

and more 22 locations

A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)

Recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: Apremilast
Drug: Deucravacitinib

First Posted Date: 2024-04-25

Last Posted Date: 2024-04-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 600

Registration Number: NCT06382987

Locations: 🇯🇵
Mebix. Inc., Minato-ku, Tokyo, Japan
🇯🇵
Fukuoka University Hospital, Fukuoka, Japan

COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Active, not recruiting

Conditions: Hypertrophic Cardiomyopathy (HCM)

Interventions: Drug: Approved Hypertrophic Cardiomyopathy drug treatments
Drug: Mavacamten

First Posted Date: 2024-04-18

Last Posted Date: 2024-04-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 500

Registration Number: NCT06372457

Locations: 🇺🇸
IQVIA, Durham, North Carolina, United States

Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada

Completed

Conditions: Upper Gastrointestinal Cancer

Interventions: Drug: Nivolumab

First Posted Date: 2024-04-12

Last Posted Date: 2024-04-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 700

Registration Number: NCT06361576

Locations: 🇨🇦
Bayshore Specialty Rx Ltd., Mississauga, Ontario, Canada

Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada

Completed

Conditions: Upper Gastrointestinal Cancer

Interventions: Drug: Nivolumab

First Posted Date: 2024-04-12

Last Posted Date: 2024-04-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 250

Registration Number: NCT06361563

Locations: 🇨🇦
Bayshore Specialty Rx Ltd., Mississauga, Ontario, Canada

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

Recruiting

Conditions: Chronic Lymphocytic Leukaemia
Multiple Myeloma
Non-Hodgkin Lymphoma

Interventions: Biological: Lisocabtagene maraleucel
Biological: Idecabtagene vicleucel

First Posted Date: 2024-04-10

Last Posted Date: 2025-04-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 50

Registration Number: NCT06357754

Locations: 🇺🇸
Local Institution - 0010, Salt Lake City, Utah, United States
🇺🇸
Local Institution - 0004, Madison, Wisconsin, United States
🇨🇭
Kantonsspital Aarau, Aarau, Switzerland

and more 2 locations

A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment

Phase 1

Recruiting

Conditions: Hepatic Impairment
Healthy Volunteers

Interventions: Drug: Repotrectinib

First Posted Date: 2024-04-08

Last Posted Date: 2024-07-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT06352528

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Local Institution - 0005, Orlando, Florida, United States
🇺🇸
Local Institution - 0006, Miami Lakes, Florida, United States

and more 3 locations

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

Active, not recruiting

Conditions: Advanced Renal Cell Carcinoma (aRCC)

Interventions: Combination Product: Pembrolizumab + Lenvatinib combination therapy
Combination Product: Nivolumab + Ipilimumab combination therapy

First Posted Date: 2024-04-03

Last Posted Date: 2024-08-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 327

Registration Number: NCT06345183

Locations: 🇺🇸
Cardinal Health, Dublin, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy